# **1** Investigating the Relationship Between Radiotherapy Dose

# 2 on the neurogenic niches and Overall Survival in NSCLC

# **3 Brain Metastases**

Fia Cialdella MD <sup>1,2</sup>, Danique E. Bruil BSc., A.T.J. van der Boog MD MSc <sup>1</sup>, Steven H.J Nagtegaal MD
PhD<sup>1,3</sup>, F.Y.F. de Vos MD PhD <sup>2</sup>, J.J.C. Verhoeff MD PhD <sup>1</sup>, Szabolcs David PhD

6 1. Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, The Netherlands

- 7 2. Department of Medical Oncology, University Medical Center Utrecht, Utrecht, The Netherlands
- 8 3. Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, The Netherlands
- 9

## 10 Summary

**Background** Non-small cell lung cancer (NSCLC), the most common type of lung cancer, often leads to brain metastases (BMs) with a poor prognosis. Radiotherapy is the main treatment for BMs, which despite decades of development, still results in radiation of healthy tissue. Neural stem cells (NSCs), crucial for the establishment and preservation of the nervous system, are sensitive to radiation, therefore radiation damage to NSCs may affect overall survival (OS). NSCs are primarily located in the subventricular zone (SVZ) and the subgranular zone (SGZ) within the hippocampus (HPC). Our study aims to evaluate the impact of radiotherapy dose on NSCs on OS in patients with BMs from NSCLC.

18 **Methods** We have retrospectively included 138 NSCLC patients with BMs, irradiated at a single 19 academic institute. NSC regions were delineated on the non-enhanced T1 MR images with CAT12 and 20 SPM. The association between regional mean doses in the SVZ and HPC and OS was examined using a 21 Cox regression model. Additionally, survival differences between lesion contact and no direct contact 22 with SVZ and HPC were investigated with Kaplan-Meier (KM) analysis.

Findings Multivariable Cox regression of dose on the SVZ and HPC showed a significant negative
correlation, with a hazard ratio (HR) of 1.366 (p = 0.041 [95% (Cl) 1.013– 1.842]) and 1.194 (p = 0.037
[95% Cl 1.010 – 1.411]), respectively. KM analysis did not find a relationship between lesion contact
with NSC-regions and OS.

27

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Interpretation Radiotherapy dose on the neurogenic niches is correlated with poorer OS and we found no association between direct lesion contact to NSC-regions and OS. We recommend further investigation into the impact of radiation on OS and neurocognitive function in a prospective study design in order to develop treatment approaches that minimize the potential harm to NSC's while maximizing effectiveness.

33 **Funding** Received no funds, grants, or support.

Keywords Brain metastases (BMs), Non-small cell lung cancer, radiotherapy, irradiation, neurogenic
 niches, neural stem cells (NSCs), subventricular zone (SVZ); hippocampus (HPC), subgranular zone
 (SGZ)

### 37 BACKGROUND

#### 38 Lung cancer and brain metastases

The majority of patients with lung cancer are diagnosed with Non-Small Cell Lung Cancer (NSCLC), of 39 40 which Lung Adenocarcinoma (LUAD ~50%) and Lung Squamous Cell Carcinoma (LUSC ~40%) are the most common types.<sup>1</sup> A frequent complication of NSCLC is the development of brain metastases 41 42 (BMs). The incidence has increased recent years due to more sensitive detection methods for BMs, 43 longer life expectancy of cancer patients due to improved systemic therapy against the primary tumor, and because of an ageing population being more prone to developing cancers.<sup>2</sup> The exact prevalence 44 45 of BMs in NSCLC is unknown, with studies reporting a risk rate of 10% to 36% to develop BMs during the disease course.<sup>3-6</sup> Overall survival (OS) of these patients varies from median 2 to 9 months 46 47 depending on type of treatment.<sup>7,8</sup> BMs are treated by either local radiotherapy (RT) or a combined treatment of surgical resection and subsequent RT. The aim of local therapy is to improve OS and to 48 49 alleviate symptomatic progression of the BMs.<sup>9</sup> The preferred type of radiotherapy is stereotactic 50 radiosurgery (SRS), in which targeted radiation is delivered with high precision to the BMs - usually in 51 a large, single fraction - to improve local tumor control. The prescribed SRS dose is calculated by the 52 volume or axial size of the BMs based-on contrast enhanced T1-weighted MR imaging, while keeping the presumed risk of radiation damage to the surrounding tissue in mind.<sup>10</sup> Whole-brain radiotherapy 53 54 (WBRT) is also used to treat multiple BMs (e.g. more than 10), as prophylactic treatment of microscopic BMs in Small Cell Lung Cancer or as symptomatic treatment in terminal stage of the 55 56 disease.<sup>11</sup> However, due to this risk of toxicity, SRS is preferred over WBRT.<sup>12</sup>

Previous studies on general cranial radiotherapy (RT) indicate that RT can damage healthy brain tissue,
leading to atrophy or damage that may subsequently result in cognitive impairment or other
neurological disorders.<sup>13,14</sup>

Radiation therapy that irradiates neural stem cells (NSCs) can potentially have a negative impact on
both OS and Quality of Life (QoL) due to the presumed effects on the repair of radiation-induced
damage to the brain.<sup>15</sup>

#### 63 Neurogenic niches in adults

64 NSCs are located in the so called *neurogenic niches*, which involve two separate regions in the adult brain: (1) the subventricular zone (SVZ), situated underneath the ependymal layer of cells that line the 65 ventricles and (2) the subgranular zone (SGZ), part of the hippocampal dentate gyrus.<sup>16</sup> NSCs induce 66 67 neurogenesis, which is the process of generating new neurons from NSCs. This process allows cell 68 replacement after neuron loss triggered by brain injury (e.g. due to tumor growth, surgery or 69 radiotherapy).<sup>17</sup> Additionally, adult NSCs, particularly in the hippocampus (HPC) also play a role in the 70 regulation of several cognitive proccesses.<sup>18</sup> Irradiation of the neurogenic niches is hypothesized to 71 play a role in reducing adult neurogenesis in two ways: inducing acute apoptosis in dividing cells and 72 reducing the production of new neurons by decreasing the pool of mitotic NSCs.<sup>19</sup>

A recent study by our group examined the relationship between tumor contact and irradiation of the neurogenic niches<sup>20</sup> in glioma patients, where we showed that a tumor which invades the SVZ region has decreased survival compared to patients without SVZ-tumor invasion. No association was observed for hippocampus-tumor invasion. We also found that irradiation of the neurogenic areas leads to a worser OS in patients with high grade glioma. According to the findings of this study, avoiding irradiation of the neurogenic niches in patients with glioma may result in a better OS.

The survival of lung cancer patients is increasing due to improved therapies such as molecularly targeted therapies <sup>5</sup> and the incidence of BMs is rising.<sup>2</sup> To extend the survival of this patient group through appropriate radiotherapy and minimize the negative impact on their QoL, further research is necessary. Therefore, this retrospective study aims to investigate the effect of radiotherapy dose on neurogenic niches on OS in a cohort of NSCLC patients with BMs. Our hypothesis is that any dose on the neurogenic niches or overlap between lesions and neurogenic niches would result in lower OS.

#### 86 MATERIAL AND METHODS

#### 87 Patient Selection and clinical data collection

We retrospectively selected patients with BMs from NSCLC, who underwent SRS at a single academic 88 89 center, the UMC Utrecht (UMCU), between December 2014 and April 2020. All patients have been 90 referred from the UMC Utrecht and surrounding general hospitals in the Utrecht region, where they 91 were treated for NSCLC. Inclusion criteria were: patients diagnosed with NSCLC, age  $\geq$ 18 years and 92 accessible RT planning and dosimetry data. Patients with a karnofsky performance status (KPS) of less 93 than 70 were only included if there was an expectation of neurological improvement as an effect of 94 stereotactic radiosurgery. Exclusion criteria were neuro endocrine pathology and prior intracranial 95 radiotherapy. OS was monitored until June 28<sup>th</sup> 2022 and censored afterwards. Clinical data was extracted from the electronic health record (HiX, Chipsoft, The Netherlands) or from referral data and 96 97 included demographics (age, gender) as well as clinical information such as type of NSCLC, number 98 and location of BMs, and prior systemic therapies (i.e., chemotherapy, immunotherapy and targeted therapy). Type of lung cancer was divided in (1) LUAD, including undifferentiated large cell carcinoma, 99 100 and (2) LUSC. The WHO performance status was calculated based on the KPS by means of the oncology 101 practice tool.<sup>21</sup> Gross total volume (GTV) and planning target volume (PTV) were delineated for clinical 102 purposes by a radiation oncologist. The UMC Utrecht Medical Ethics Research Committee assessed 103 the study protocol and waived the need for informed consent (METC 18-273).

#### 104 Image processing and segmentation

105 Briefly, patients underwent pre-treatment MR scans on a 3T Philips scanner (Philips Healthcare, Best, 106 The Netherlands) as part of standard clinical care. We collected the 3D turbo-spin echo (TSE) T1-107 weighted MR images without contrast enhancement, with the following parameters: TR = 8.1 ms, TE 108 = 3.7 ms, flip angle =  $8^\circ$ , voxel resolution  $1 \times 0.96 \times 0.96$  mm. The planning CT scans were acquired on 109 a Brilliance Big bore scanner (Philips Medical Systems, Best, The Netherlands), with a tube potential 110 of 120 kVp, using a matrix size of  $512 \times 512$  and  $0.65 \times 0.65 \times 3.0$  mm voxel size. While automated 111 segmentation of MR images with common neuroimaging software, e.g.: FSL, SPM and FreeSurfer has great performance, it is often challenging and lead to unsatisfactory results when mayor abnormalities 112 113 are present in the brain, such as BM lesions. In order to facilitate the segmentation, first we replaced 114 all the abnormal tissues, that is edema, tumor cavity, etc., with healthy appearing, but fake tissue, which process is also called virtual brain grafting (VBG).<sup>22</sup> This allowed the automatic delineation of 115 the SVZ and hippocampus regions on the VBG-enhanced T1 MR images with CAT12. The readers are 116 kindly referred to our previous work at Bruil et al (2022).<sup>20</sup>, which describe the fine details of all image 117 118 processing. An example of delineation and radiotherapy plan is presented in Figure 1. After the

- process finished, regions and labels covering the fake tissue were ignored from further analysis, therefore only the non-affected parts of SVZ and hippocampus were considered. Mean dose per SVZ and hippocampi labels were calculated for further analyses, while SVZ/hippocampi to lesion contact was defined when SVZ/hippocampi labels from the aforementioned segmentation process were part of the replaced fake tissue. In case SVZ/hippocampi labels were outside of the fake tissue, it is considered no lesion contact.
  - Single Lesion Example Multi Lesion Example HC H HC HC

125

Figure. 1: An example of delineation and radiotherapy Two example patients' radiotherapy plan and the SVZ, hippocampus delineations, respectively. The patient on the left has a single brain metastatic lesion, which is distal from the both SVZ and hippocampus, while the patient of the right has two BM lesions of which one is proximal the neurogenic niches. The top two rows show the CT scan along with the PTV and CTV in blue and red respectively as well as the dose distribution. The bottom two rows show the SVZ and a hippocampus segment. Radiological view: left is right.

#### 133 Dose calculation

Typically, a single fraction of RT was prescribed. In case of multiple fractions given instead of a single treatment, the dose was recalculated in single fraction equivalent dose (SFED). We defined SFED as the dose delivered in a single fraction that would have the same biologic effect as the dosefractionation scheme, according to the method by *Park et al.* (2008)<sup>23</sup>

138

#### 139 Statistical Analyses


140 The relationship between OS, lesion contact and mean dose per neurogenic niche region were analyzed with IBM SPSS (for Windows, version 25). The primary outcome of this study was OS, defined 141 142 as months after the RT until date of death. In this study, we utilized Kaplan-Meier (KM) analyses to 143 investigate the impact of lesion contact with the neurogenic niches on OS in patients. Specifically, we 144 compared patients who had lesion contact with the neurogenic niches to those who did not. Additionally, we conducted multivariable Cox-regression analyses, corrected for the covariates 145 outlined in the results section, to analyze OS. We set statistical significance at p <0.05. Furthermore, 146 147 we used the Variance Inflation Factor (VIF) to evaluate the presence of multi-collinearity among all covariates for each independent variable. 148

#### 150 **RESULTS**

#### 151 Participants

152 From December 2014 to April 2020, we identified 802 patients who underwent RT for BMs at the UMCU. Among these patients, 389 had previously received intracranial RT, such as SRS, WBRT or 153 154 prophylactic cranial irradiation (PCI), and were therefore excluded from the study. Of the 413 patients who met the inclusion criteria, 141 were diagnosed with BMs from non-small cell lung cancer (NSCLC). 155 156 After excluding 3 patients with neuroendocrine pathology, the final study cohort comprised 138 patients. The patient inclusion flowchart is shown in Figure 2. Baseline patient and treatment 157 158 characteristics are shown in Table 1. The median age was 67 years (interquartile range 60 -74) and the male-female distribution was even. 28 (20%) patients underwent surgery prior to RT of whom 21 159 160 patients had a complete macroscopic resection of one lesion, next to other unresected BMs. A total of 29.7% of the patients received a concurrent combination of chemotherapy and other systemic 161 treatments, 28.4% was treated by chemotherapy alone and 19.1% received immunotherapy/target 162 163 therapy only.





#### 165 Figure 2: Flowchart of patient inclusion

- 168
- 169

<sup>166</sup> RT: Radiotherapy, SRS: Stereotactic radiosurgery, WBRT: Whole brain radiotherapy, PCI: Prophylactic cranial

<sup>167</sup> irradiation, NSCLC; non-small cell lung cancer

Patient count (%)	138 (100)		
Median age in years (Range)	67 (60 -74)		
Sex			
Female (%)	69 (50)		
Male (%)	69 (50)		
WHO performance status			
0 (%)	30 (21.7)		
1 (%)	86 (62.3)		
2 (%)	11 (8.0)		
3 (%)	4 (2.9)		
Missing (%)	7 (5.1)		
Type of lung cancer			
LUAD (%)	102 (73.9)		
LUSC (%)	21 (15.2)		
Missing (%)	15 (10.9)		
Total intracranial volume in cm3 (IQR)	1467 (1383 – 1576)		
SVZ volume in mm3 (IQR)	10794 (9267 – 13258)		
SGZ volume in mm3 (IQR)	1607 (1481 – 1757)		
Number of brain metastases			
1 (%)	68 (49.3)		
2-4 (%)	54 (39.1)		
>4 (%)	16 (11.6)		
Subventricular zone-tumor contact			
Yes (%)	34 (24.6)		
No (%)	104 (75.4)		
Hippocampus-tumor contact			
Yes (%)	10 (7.2)		
No (%)	128 (92.8)		
Single-fraction equivalent dose (IQR)	21 (21 – 24)		
Median RT dose in SVZ in Gy (IQR)	1.50 (0.86-2.73)		
Median RT dose in HPC in Gy (IQR)	1.24 (0.48 – 2.25)		
Number of fractions			
1 (%)	114 (82.6)		
3 (%)	23 (16.7)		
5 (%)	1 (0.7)		
Brain surgery			
Yes (%)	28 (20.3%)		
No (%)	110 (79.7%)		
Extent of surgery			
Partial resection (%)	7 (25%)		
Complete resection (%)	21 (75%)		
Any chemotherapy			
Yes (%)	81 (58.7)		
No (%)	54 (39.1)		
Missing (%)	3 (2.2)		
Any other systemic therapy			
Yes (%)	67 (48.6)		
No (%)	66 (47.8)		
Missing (%)	5 (3.6)		


170 LUAD: Lung Adenocarcinoma, LUSC: Lung Squamous Cell Carcinoma, RT: Radiotherapy, SVZ: Subventricular


171 zone, SGZ: Subgranular zone

#### 173 Survival Analysis

179

- 174 At time of censoring, 107 (78%) of the 138 patients within our cohort had deceased, with a median OS
- 175 from start of RT of 8.4 months (range 0.23 64.7 months). In LUAD, we observed a median OS rate of
- 176 9.6 months and for LUSC 5.1 months, which were not significantly different (p = 0.461). As can be seen
- in Figure 3 and Table 2, we found no association between OS and lesion contact with the SVZ or HPC
- 178 in univariate, nor different multivariate setups.





181 Kaplan-Meier overall survival according to tumor contact with the hippocampus (HPC).

182 HR=hazard ratio. LUAD=lung adenocarcinoma. LUSC=lung squamous cell carcinoma

# Table 2: Univariable and multivariable Cox regression analysis of no tumor contact/tumor contact with the subventricular zone (SVZ) on overall survival (OS). Analyses with p < 0.05 are considered significant and bolded in the table.

and bolded in the	lable.	1		
Univariable:		p-value		0.465
		HR		1.177
		95.0 % CI	Lower	0.750
		95.0 % CI		0.760
			Upper	1.823
Multivariable,	Age, Sex, WHO performance status, type	P-value		0.336
corrected for:	of lung cancer, SVZ volume	HR		1.265
				0.783
		95.0% CI	Lower	
			Upper	2.042
Multivariable,	Age, Sex, WHO performance status, type	p-value		0.047
corrected for:	of lung cancer, SVZ volume, number of	HR		1.670
	brain metastases, metastases elsewhere			
	in the body, chemotherapy, any other	95.0% CI	Lower	1.006
	systemic therapy, resection extent		Upper	2.773
Multivariable,	Age, Sex, WHO performance status, type	p-value		0.220
corrected for:	of lung cancer, SVZ volume, number of	HR		1.472
	brain metastases, metastases elsewhere			
	in the body, chemotherapy, any other	95.0% CI	Lower	0.794
	systemic therapy, resection extent, %		Upper	2.727
	PTV within the SVZ			

183

Table 3: Univariable and multivariable Cox regression analysis of no tumor contact/tumor contact with
the hippocampus (HPC) on overall survival (OS). Analyses with p < 0.05 are considered significant and
bolded in the table.

bolded in the ta	able.			
Univariable:		p-value		0.852
		HR		0.930
		95.0% CI	Lower	0.404
			Upper	0.431
			opper	2.003
Multivariable,	Age, Sex, WHO performance status, type	p-value		0.209
corrected for:	of lung cancer, SGZ volume	HR		1.692
		95.0 % CI	Lower	0.745
			Upper	3.843
Multivariable,	Age, Sex, WHO performance status, type	p-value		0.157
corrected for:	of lung cancer, SGZ volume, number of	HR		1.839
	brain metastases, metastases elsewhere in			
	the body, chemotherapy, any other	95.0% CI	Lower	0.791
	systemic therapy, resection extent		Upper	4.275
Multivariable,	Age, Sex, WHO performance status, type	p-value		0.163
corrected for:	of lung cancer, SGZ volume, number of	HR		1.821
	brain metastases, metastases elsewhere in			
	the body, chemotherapy, any other	95.0% CI	Lower	0.784
	systemic therapy, resection extent, % PTV		Upper	4.231
	within the SGZ			

184 HPC: Hippocampus, SGZ: subgranular zone, PTV: Planned target volume.

185 **Table 4** and **5** show the results of the univariate- and multivariate Cox-regression between mean

186 SVZ/HPC dose and OS, respectively. Both the radiotherapy dose on SVZ and HPC have a significant

- 187 negative association with OS after adjustment for covariates with HR of 1.366 (p = 0.041 [95%
- 188 confidence interval (CI) 1.013– 1.842]) and 1.194 (p = 0.037 [95% CI 1.010 1.411]), respectively.

	able and multivariable Cox regression analysis I survival (OS). Analyses with p < 0.05 are consid			
table.				
Univariable:		p-value		0.136
		HR		1.103
		95.0% CI	Lower	0.979
			Upper	1.255
Multivariable,	Age, Sex, WHO performance status, type of	p-value	•	0.032
corrected for:	lung cancer, SVZ volume	HR		1.149
		95.0%	Lower	1.012
		55.0% CI	Upper	1.305
Multivariable,	Age, Sex, WHO performance status, type of	p-value	opper	0.008
corrected for:	lung cancer, SVZ volume, number of brain	HR		1.223
	metastases, metastases elsewhere in the			-
	body, chemotherapy, immunotherapy,	95.0% CI	Lower	1.054
	resection extent		Upper	1.418
Multivariable,	Age, Sex, WHO performance status, type of	p-value		0.041
corrected for:	lung cancer, SVZ volume, number of brain	HR		1.366
	metastases, metastases elsewhere in the			
	body, chemotherapy, immunotherapy,	95.0% CI	Lower	1.013
	resection extent, % PTV within the SVZ		Upper	1.842

189 SVZ: subventricular zone, PTV: Planned target volume.

Table 5: Univa	iable and multivariable Cox regression analysis	s of dose on t	he hippocam	pus (HPC) on
	<b>I (OS).</b> Analyses with $p < 0.05$ are considered sig			
Univariable:		p-value		0.087
		HR		1.113
		95.01% CI	Lower	0.984
			Upper	1.258
Multivariable,	Age, Sex, WHO performance status, type of	p-value		0.058
corrected for:	lung cancer, SGZ volume	HR		1.144
		95.0% CI	Lower	0.996
			Upper	1.314
Multivariable,	Age, Sex, WHO performance status, type of	p-value		0.091
corrected for:	lung cancer, SGZ volume, number of brain	HR		1.146
	metastases, metastases elsewhere in the			
	body, chemotherapy, any other systemic	95.0% CI	Lower	0.978
	therapy, resection extent		Upper	1.341
Multivariable,	Age, Sex, WHO performance status, type of	p-value		0.037
corrected for:	lung cancer, SGZ volume, number of brain	HR		1.194
	metastases, metastases elsewhere in the			
	body, chemotherapy, any other systemic	95.0% CI	Lower	1.010
	therapy, resection extent, % PTV within the		Upper	1.411
	SGZ			

- 190 HPC: Hippocampus, SGZ: subgranular zone, PTV: Planned target volume.
- 191 Our study showed that WHO performance status is correlated to OS.

#### 192 **DISCUSSION**

193 This retrospective study was designed to determine the effect of radiotherapy dose from the 194 neurogenic niches on OS and if lesion contact with the SVZ or the HPC regions affect OS in patients 195 with BMs from NSCLC.

196 Multivariate cox regression analysis showed a negative association between OS and radiotherapy dose 197 on the SVZ or the HPC after adjusting for confounding variables. The SVZ plays a pivotal role in neurogenesis and brain repair mechanisms in adults, as reported by Capilla-Gonzalez et al. (2016).<sup>15</sup> 198 199 Therefore, it could be hypothesized that reduced brain repair capacity due to radiation-induced 200 damage to the SVZ may contribute to the negative impact on OS. In addition, previous research has 201 highlighted the role of adult NSCs of the HPC in regulating cognitive function such as learning and memory.<sup>18</sup> Moreover, literature suggest that, independent of initial level of cognition, a faster decline 202 of cognitive function is associated with a higher mortality.<sup>24</sup> Based on such functions, the importance 203 204 of hippocampal avoidance to maintain neurocognitive function is established. In line with this, clinical 205 trials already have supported this observation by demonstrating that hippocampal avoidance during 206 whole-brain radiation therapy (HA-WBRT) can lead to a considerable decrease in cognitive decline.<sup>25</sup> 207 Currently, there is a limited number of investigations reporting the relationship between dose 208 received by the SVZ regions in CNS tumors and neurocognitive decline after radiotherapy, which 209 showed deterioration in cognition after higher radiation dose on the SVZ.<sup>26</sup> Further research should 210 be conducted to investigate this in more detail. Our ongoing 'Cohort for patient-reported Outcomes, 211 Imaging and trial inclusion in Metastatic BRAin disease' (COIMBRA) trial (*ClinicalTrials.gov Identifier:* 212 NCT05267158) is an example of such an initiative that can confirm the effect of radiation dose on the neurogenic niches on cognitive functioning of patients with BMs. 213

This current study showed no relationship between lesion contact with the neurogenic niches and OS of patients with BMs from NSCLC. Likely due to the sample size of the group with contact with the neurogenic niches, we were unable to determine whether the extent of contact has a significant impact. Previous research suggested that components of the neurogenic niches stimulate metastatic tumor growth <sup>27</sup>, suggesting that tumor growth is inhibited when this component of the neurogenic niches is disrupted by radiation damage to the NSCs. Future research should aim at gaining more insight into the role of NSCs in metastatic pathways.

The current study adds significant value to the field of neuro-oncological imaging by providing novel insights into the impact of radiotherapy dose on the neurogenic niches in NSCLC patients with BMs. The study utilized high-quality imaging data and a specially developed atlas<sup>20</sup> to enable accurate delineation of the regions of interest. Moreover, the patient population included in the study reflects the average patient with BMs from NSCLC, increasing the generalizability of the findings. These strengths enhance the potential clinical significance and impact of the study, providing a strong foundation for future research in this area.

228 There are several limitations to our study. Ideally, we had a more even distribution between the group 229 with the patients with lesion contact with the SVZ or HPC and the patients without, as this would give 230 our statistical analysis more power and would give us the opportunity to also investigate the subject 231 in subgroups such as type of lung cancer and number of BMs. Nevertheless, previous studies already 232 suggested that the overall risk for the incidence of metastases in the neurogenic niches is quite low. 233 <sup>17,28</sup> It seems that our cohort is an accurate reflection of the population and lesion contact with the neurogenic niches is indeed less common. While the inclusion of patients referred from multiple 234 235 hospitals allowed for a more diverse patient population in the study, one disadvantage is the 236 occurrence of missing data regarding specific gene mutations and progression free survival (PFS).

237 Our study shows a median OS of 8.3 months in selected patients with BMs from NSCLC. Furthermore, 238 the results indicate that any RT dose to the neurogenic niches is correlated with poorer OS in these 239 patients, which is in line with results in our previous study in glioma patients. Based on these data, we 240 suggest that avoidance of these niches is important to extent the OS. However, in a broader NSCLC population with BMs, without any treatment the median survival is only 2 months.<sup>7,29</sup> When avoidance 241 of the neurogenic niches with radiation is not possible, it is important to carefully consider the 242 243 potential risks and benefits of RT in patients with BMs from NSCLC. To verify our OS results and explore the effects on neurocognitive functioning in patients with BMs it is necessary to conduct comparable 244 245 clinical trials prospectively involving larger cohorts of patients suffering from BMs such as the 246 COIMBRA trial.

## 248 DATA AVAILABILITY STATEMENT

249 The data will be made available upon publication.

## 251 **REFERENCES**

- Nooreldeen R, Bach H. Current and future development in lung cancer diagnosis. Vol. 22,
   International Journal of Molecular Sciences. 2021.
- Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence Proportions of
   Brain Metastases in Patients Diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer
   Surveillance System. Journal of Clinical Oncology. 2004 Jul 15;22(14):2865–72.
- Fenske DC, Price GL, Hess LM, John WJ, Kim ES. Systematic Review of Brain Metastases in
   Patients With Non–Small-Cell Lung Cancer in the United States, European Union, and Japan.
   Clin Lung Cancer. 2017 Nov 1;18(6):607–14.
- Nayak L, Lee EQ, Wen PY. Epidemiology of brain metastases. Curr Oncol Rep. 2012;14(1):48–
   54.
- Sperduto PW, Yang TJ, Beal K, Pan H, Brown PD, Bangdiwala A, et al. Estimating survival in
   patients with lung cancer and brain metastases an update of the graded prognostic
   assessment for lung cancer using molecular markers (Lung-molGPA). Vol. 3, JAMA Oncology.
   2017. p. 827–31.
- Mujoomdar A, Austin JHM, Malhotra R, Powell CA, Pearson GDN, Shiau MC, et al. Clinical
   Predictors of Metastatic Disease to the Brain from Non–Small Cell Lung Carcinoma: Primary
   Tumor Size, Cell Type, and Lymph Node Metastases. Radiology. 2007 Mar;242(3):882–8.
- Peters S, Bexelius C, Munk V, Leighl N. The impact of brain metastasis on quality of life,
   resource utilization and survival in patients with non-small-cell lung cancer. Cancer Treat Rev.
   2016 Apr;45:139–62.
- Hatton N, Samuel R, Riaz M, Johnson C, Cheeseman S, Snee M. A study of non small cell lung
   cancer (NSCLC) patients with brain metastasis: A single centre experience. Cancer Treat Res
   Commun [Internet]. 2023 Jan 1 [cited 2023 Jan 11];34:100673. Available from:
   https://linkinghub.elsevier.com/retrieve/pii/S2468294222001642
- Goldberg SB, Contessa JN, Omay SB, Chiang V. Lung Cancer Brain Metastases. The Cancer
   Journal. 2015 Sep;21(5):398–403.
- Shaw E, Scott C, Souhami L, Dinapoli R, Kline R, Loeffler J, et al. Single dose radiosurgical
   treatment of recurrent previously irradiated primary brain tumors and brain metastases: final
   report of RTOG protocol 90-05. International Journal of Radiation Oncology\*Biology\*Physics.
   2000 May;47(2):291–8.
- McTyre E, Scott J, Chinnaiyan P. Whole brain radiotherapy for brain metastasis. Surg Neurol
   Int. 2013;4(Suppl 4):S236-44.
- Brown PD, Ballman K v., Cerhan JH, Anderson SK, Carrero XW, Whitton AC, et al.
   Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for
   resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised,
   controlled, phase 3 trial. Vol. 18, The Lancet Oncology. 2017. p. 1049–60.
- Nagtegaal SHJ, David S, van Grinsven EE, van Zandvoort MJE, Seravalli E, Snijders TJ, et al.
   Morphological changes after cranial fractionated photon radiotherapy: Localized loss of white

290 291		matter and grey matter volume with increasing dose. Clin Transl Radiat Oncol. 2021 Nov;31:14–20.
292 293 294 295	14.	Nagtegaal SHJ, David S, Philippens MEP, Snijders TJ, Leemans A, Verhoeff JJC. Dose- dependent volume loss in subcortical deep grey matter structures after cranial radiotherapy. Clin Transl Radiat Oncol [Internet]. 2021 Jan 1 [cited 2023 Mar 28];26:35. Available from: /pmc/articles/PMC7691672/
296 297 298	15.	Capilla-Gonzalez V, Bonsu JM, Redmond KJ, Garcia-Verdugo JM, Quiñones-Hinojosa A. Implications of irradiating the subventricular zone stem cell niche. Stem Cell Res. 2016 Mar;16(2):387–96.
299 300 301	16.	Achanta P, Capilla-Gonzalez V, Purger D, Reyes J, Sailor K, Song H, et al. Subventricular zone localized irradiation affects the generation of proliferating neural precursor cells and the migration of neuroblasts. Stem Cells. 2012;30(11):2548–60.
302 303 304	17.	Wan JF, Zhang SJ, Wang L, Zhao K le. Implications for preserving neural stem cells in whole brain radiotherapy and prophylactic cranial irradiation: A review of 2270 metastases in 488 patients. J Radiat Res. 2013;54(2):285–91.
305 306	18.	Khacho M, Harris R, Slack RS. Mitochondria as central regulators of neural stem cell fate and cognitive function. Nat Rev Neurosci. 2019 Jan;20(1):34–48.
307 308	19.	Michaelidesová A, Konířová J, Bartůněk P, Zíková M. Effects of radiation therapy on neural stem cells. Genes (Basel). 2019;10(9).
309 310 311 312	20.	Bruil DE, David S, Nagtegaal SHJ, de Sonnaville SFAM, Verhoeff JJC. Irradiation of the subventricular zone and subgranular zone in high- and low-grade glioma patients: an atlasbased analysis on overall survival. Neurooncol Adv [Internet]. 2022 Jan 1;4(1):1–12. Available from: https://academic.oup.com/noa/article/doi/10.1093/noajnl/vdab193/6506538
313 314 315	21.	Oken MM, Creech RH, Davis TE. Toxicology and response criteria of the Eastern Cooperative Oncology Group. Vol. 5, American Journal of Clinical Oncology: Cancer Clinical Trials. 1982. p. 649–55.
316 317 318	22.	Radwan AM, Emsell L, Blommaert J, Zhylka A, Kovacs S, Theys T, et al. Virtual brain grafting: Enabling whole brain parcellation in the presence of large lesions. Neuroimage. 2021 Apr 1;229:117731.
319 320 321	23.	Park C, Papiez L, Zhang S, Story M, Timmerman RD. Universal Survival Curve and Single Fraction Equivalent Dose: Useful Tools in Understanding Potency of Ablative Radiotherapy. Int J Radiat Oncol Biol Phys. 2008;70(3):847–52.
322 323 324 325	24.	van Gelder BM, Tijhuis MAR, Kalmijn S, Giampaoli S, Kromhout D. Decline in Cognitive Functioning Is Associated with a Higher Mortality Risk. Neuroepidemiology [Internet]. 2007 [cited 2023 Mar 28];28(2):93–100. Available from: https://www.karger.com/Article/FullText/98552
326 327 328 329	25.	Gondi V, Pugh SL, Tome WA, Caine C, Corn B, Kanner A, et al. Preservation of Memory With Conformal Avoidance of the Hippocampal Neural Stem-Cell Compartment During Whole- Brain Radiotherapy for Brain Metastases (RTOG 0933): A Phase II Multi-Institutional Trial. Journal of Clinical Oncology. 2014 Dec 1;32(34):3810–6.

- Valiyaveettil D, G A, Malik M, Eaga P, Ahmed SF, Joseph D. "A prospective study of
  assessment of neurocognitive function in illiterate patients with gliomas treated with
  chemoradiation": Assessment of neurocognitive function in gliomas. Cancer Treat Res
  Commun. 2021 Jan 1;26:100288.
- 334 27. Hoshide R, Jandial R. The role of the neural niche in brain metastasis. Clin Exp Metastasis.
  335 2017;34(6–7):369–76.
- Oskan F, Ganswindt U, Schwarz SB, Manapov F, Belka C, Niyazi M. Hippocampus sparing in
   whole-brain radiotherapy: A review. Strahlentherapie und Onkologie. 2014;190(4):337–41.
- Jeene PM, de Vries KC, van Nes JGH, Kwakman JJM, Wester G, Rozema T, et al. Survival after
  whole brain radiotherapy for brain metastases from lung cancer and breast cancer is poor in
  6325 Dutch patients treated between 2000 and 2014. Acta Oncol (Madr). 2018
  May;57(5):637–43.
- 342